Related Experiment Videos
High dose Ara-C related leukoencephalopathy.
Journal of Neuro-Oncology
|January 1, 1986
Summary
High-dose cytarabine (Ara-C) therapy can cause leukoencephalopathy in acute myelomonocytic leukemia patients. This neurological complication may result from Ara-C
Area of Science:
- Neuro-oncology
- Hematology
- Pharmacology
Background:
- Acute myelomonocytic leukemia (AMML) can relapse in the central nervous system (CNS).
- High-dose cytarabine (Ara-C) is used in treating hematological malignancies, including AMML.
- CNS leukemia relapse often requires intensive therapeutic strategies.
Observation:
- Two patients with CNS relapse of AMML developed leukoencephalopathy after high-dose intravenous Ara-C.
- Clinical and neuroimaging findings consistent with leukoencephalopathy appeared 5-7 days post-therapy.
- One patient received combined therapy (intravenous Ara-C, cranial irradiation, intrathecal Ara-C); the other received prior intrathecal chemotherapy.
Findings:
- Leukoencephalopathy in the first patient was likely due to synergistic effects of triple therapy.
- Intravenous Ara-C was the probable precipitating factor in the second patient.
- Altered mental status and white matter changes on CT scan indicated leukoencephalopathy.
Implications:
- High-dose Ara-C, particularly in combination regimens, poses a risk of neurotoxicity.
- Understanding Ara-C induced leukoencephalopathy mechanisms is crucial for patient management.
- This highlights the need for careful monitoring of neurological function during intensive chemotherapy for CNS leukemia.